(HealthDay)—For adult patients with Crohn's disease, adalimumab and infliximab + azathioprine are most effective for induction and maintenance of remission, according to a meta-analysis published in the February issue of ...
Jan 28, 2015
0
6
(HealthDay) -- All patients with psoriasis should be screened for hepatitis B surface antigen and hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy, according to research published ...
Jul 1, 2012
0
0
An antibody used to treat the skin disease psoriasis and other chronic autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease has no effect on aortic inflammation—a key marker of future risk of ...
May 18, 2018
0
5
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, ...
May 25, 2011
0
0
(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment with once-weekly ...
Dec 18, 2012
0
0
(HealthDay)—Adalimumab exposure in pregnancy does not increase the risk for birth defects, according to a study published online Oct. 18 in PLOS ONE.
Nov 1, 2019
0
1
(HealthDay)—In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 ...
Mar 28, 2019
0
3
(HealthDay)—In a case report published online Feb. 12 in the Journal of Clinical Pharmacy and Therapeutics, drug-induced lupus erythematosus (DILE) is described in a patient taking adalimumab for psoriasis.
Feb 20, 2017
0
2
(HealthDay)—Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.
Oct 1, 2012
0
0
New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), ...
Aug 8, 2012
0
0
